Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer

Colorectal Cancer Clinical Trial

— ICOG  

Official title:

Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00497107
• Other study ID #: ICOG-CC01
• Status: Recruiting
• Phase: Phase 3
• First received: July 5, 2007
• Last updated: July 30, 2008
• Start date: July 2007
• Est. completion date: May 2013

Study information

• Verified date: July 2008
• Source: Iwate Medical University
• Contact: Go Wakabayashi, MD, PhD
• Phone: +81-19-651-5111
• Email: gowaka[@]iwate-med.ac.jp
• Is FDA regulated: No
• Health authority: Japan: Institutional Review BoardJapan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to conduct a randomised controlled trial (RCT) comparing UFT/LV and UFT/LV + PSK in patients with histological stage IIIa/IIIb colorectal cancer who have undergone curative surgery without residual cancer using 3-year disease free survival (DFS) as the primary endpoint, and also to analyze the 3-year overall survival (OS), compliance, adverse events, quality of life (QOL) and relationship with tumor factors.

Description:

To conduct a randomized controlled trial comparing chemotherapy using UFT/LV and immunochemotherapy using UFT/LV combined with PSK in patients with histological stage IIIa and IIIb colorectal cancer (adenocarcinoma) who have undergone curative surgery without residual cancer (R0) using 3-year disease-free survival rate as primary endpoint, and also to analyze the 3-year overall survival, compliance, adverse events, QOL and relationship with tumor factors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: May 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 79 Years

Eligibility

Inclusion Criteria:

• Patient with a histological diagnosis of primary colon or rectal cancer (adenocarcinoma)

• Patient with histological stage IIIa or IIIb cancer (according to the Japanese Classification of Colorectal Cancer, 7th edition)

• Patient who has undergone curative surgery with no residual cancer

• Pretreatment criterion: patient who has not undergone preoperative cancer treatment (radiotherapy, chemotherapy or immunotherapy)

• Patient who is at least 20 years and below 80 years of age

• Patient with performance status (PS) of 0-1 (according to Eastern Cooperative Oncology Group, ECOG)

• Restrictions of concomitant medications and therapies: except in the case of metastasis or recurrence, concomitant use of other chemotherapeutic and immunotherapeutic agents that may affect the results of this trial, and concomitant use of radiotherapy are prohibited in principle.

• Organ function (laboratory data): patient who satisfies the following conditions or data of laboratory tests conducted within 2 weeks prior to start of trial

• Gastrointestinal function: no diarrhea (watery stool)

• White blood cell count: > 4,000/mm3

• Platelet count: > 100,000/mm3

• Serum GOT and GPT: < 100 IU/L

• Serum total bilirubin: < 2.0 mg/dL

• Serum creatinine: below the upper limit of facility normal range

Exclusion Criteria:

• Patient with residual cancer (R1 or R2)

• Patient with anal canal lesion (P) or perianal skin lesion (E)

• Patient with stricture and not capable of oral intake

• Patient passing fresh blood from the gastrointestinal tract

• Patient with retention of body cavity fluid necessitating treatment

• Patient with infection, intestinal palsy or intestinal occlusion

• Patient with active multiple cancers or patient who has less than 5 years of remission from a metachronous cancer (except carcinoma in situ and skin cancer)

• Patient who is pregnant or wishes to become pregnant during this trial

• Patient on continuous insulin treatment for diabetes or has poorly controlled diabetes

• Patient with a history of ischemic heart disease and judged to have difficulties to participate in this trial

• Patient with concurrent psychiatric disease or neurological symptoms and judged to have difficulties to participate in this trial

• Patient on continuous steroid therapy

• Patient with a history of serious drug allergy

• Patient who is judged for other reasons by the investigator or doctor in charge to be inappropriate as a subject

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• UFT, Calcium Folinate, PSK

• UFT, Calcium Folinate

Locations

Country	Name	City	State
Japan	Iwate Medical University Hospital	Morioka	Iwate

Sponsors (1)

Lead Sponsor	Collaborator
Iwate Medical University

Country where clinical trial is conducted

Japan, 

References & Publications (2)

Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 May 1;24(13):2059-64. — View Citation

Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T, Morishita Y. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer. 2004 Mar 8;90(5):1003-10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival		3-years
Secondary	Overall survival, compliance, adverse events, QOL, tumor markers		3-years